Division of Gastroenterology

John Marshall

MD MSc FRCPC AGAF

Professor, Department of Medicine

Director, Division of Gastroenterology

Member, Farncombe Family Digestive Health Research Institute

 

 

 

Education and Professional Standing

Dr. Marshall is a Professor of Medicine and Director of the Division of Gastroenterology at McMaster University, as well as a consultant gastroenterologist at Hamilton Health Sciences in Hamilton Ontario. He completed his B.A. and M.D. at Queen’s University, and then undertook his residency training and M.Sc. in Clinical Epidemiology & Biostatistics at McMaster University. He is a Full Member of the Farncombe Family Digestive Health Research Institute. His publications include over 200 academic papers and book chapters and over 200 abstracts. Dr. Marshall is the Editor-in-Chief of the Journal of the Canadian Association of Gastroenterology (JCAG). He is alsoan Associate Editor of ACP Journal Club and Evidence-Based Medicine, an Editorial Board Member for the Journal of Crohn’s and Colitis, and an Editor for the Cochrane Collaboration Inflammatory Bowel Disease and Functional Bowel Disorders Review Group. Past honours include the Canadian Association of Gastroenterology (CAG) Young Investigator Award (2008), the CAG Young Educator Award (2006) and Fellowship in the American Gastroenterological Association (2007). Dr. Marshall’s clinical and research interests include inflammatory bowel disease, post-infectious irritable bowel syndrome, gastrointestinal bleeding, endoscopy, clinical trials, clinical epidemiology, health outcomes and health economics.

Selected Publications

  1. Marshall JK, Irvine EJ. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta analysis.  Aliment Pharmacol Ther 1995;9:292-300
  2. Irvine EJ, Marshall JK. Increased intestinal permeability precedes the onset of Crohn’s disease in a subject with familial risk.  Gastroenterology 2000;119:1740-4.
  3. Marshall JK, Blackhouse G, Goeree R, Brazier N, Irvine E, Faulkner L, Dipchand C, O’Brien B.  Infliximab for the treatment of Crohn’s disease: a systematic review and cost-utility analysis. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2002. Technology Report no 24.
  4. Barkun A, Bardou M, Marshall JK, for the Non-Variceal Upper GI Bleeding Consensus Group.  The Banff consensus conference on the management of patients with non-variceal upper gastrointestinal bleeding. Ann Intern Med 2003;139:843-57.
  5. Marshall JK, Cawdron R, Zealley I, Riddell RH, Somers S, Irvine EJ.  Prospective comparison of small bowel meal with pneumocolon versus ileoscopy for diagnosis of ileal Crohn’s disease.  Am J Gastroenterol 2004;99:1321-9.
  6. Marshall JK, Thabane M, Garg AX, Clark W, Salvadori M, Collins SM. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology 2006;131:445-50.
  7. Marshall JK, Thabane M, Borgaonkar M, James C. Post infectious irritable bowel syndrome following a foodborne outbreak of acute gastroenteritis attributed to a viral pathogen.  Clin Gastroenterol Hepatol 2007;5:457-60.
  8. Thabane M, Kottachchi D, Marshall JK. Systematic review and meta-analysis to determine incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007;15:535-44.
  9. Marshall JK, Thabane M, Steinhart AH, Newman J, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for induction of remission of ulcerative colitis. Cochrane Database Syst Rev 2010;CD004115.
  10. Villani AC, Lemire M, Thabane M, Geneau G, Belisle A, Garg AX, Clark WF, Moayyedi P, Collins SM, Franchimont D, Marshall JK.  Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology 2010;138:1502-13. Editorial: Vermeire S, Van Assche G, Rutgeerts P. Post-infectious irritable bowel syndrome: a genetic link identified? Gastroenterology 2010;138:1246-9. Commentary: Jones R. Genetic susceptibility to postinfectious IBS. Nat Rev Gastroenterol Hepatol 2010;7:1. Commentary:  Craig OF, Quigley EM. Expert Rev Gastroenterol Hepatol 2010;4:271.6. Commentary: Jones R. Nature Rev Gastroenterol  Hepatol 2010;7:301.
  11. Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM. Eight-year prognosis of post-infectious irritable bowel syndrome following waterborne bacterial dysentery. Gut 2010;59:605-11. Commentary: Wang HW, Chang L. The Walkerton outbreak revisited at year 8: predictors, prevalence and prognosis of post-infectious IBS. Gastroenterology 2011;140:726-8.
  12. Kassam Z, Hundal R, Marshall JK, Lee C. Fecal transplant via retention enema for refractory or recurrent Clostridium difficile infection. Arch Intern Med 2012;172:191-3.
  13. Blackhouse G, Assasi N, Xie F, Marshall JK, Irvine EJ, Gaebel K, Campbell K, Hopkins R, O’Reilly D, Tarride JE, Goeree R. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-alpha drugs for refractory Crohn’s disease. J Crohn Colitis 2012;6:77-85.
  14. Bitton A, Buie D, Enns R, Feagan B, Jones J, Marshall JK, Whittaker S, Griffiths A, Panaccione R, CAG Severe UC Consensus Group. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol 2012;107:179-94.
  15. Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for maintaining remission of distal ulcerative colitis. Cochrane Database Syst Rev 2012(11):CD004118.
  16. Narula N, Charleton D, Marshall JK. Meta-analysis: peri-operative anti-TNFa treatment and post-operative complications in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013;37:1057-64.
  17. Khanna R, Sattin BD, Afif W, Benchimol EI, Bernard EJ, Bitton A, Bressler B, Fedorak RN, Ghosh S, Greenberg GR, Marshall JK, Panaccione R, Seidman EG, Silverberg MS, Steinhart AH, Sy R, Van Assche G, Walters TD, Sandborn WJ, Feagan BG. A clinician’s guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther 2013;38:447-59.
  18. Nguyen GC, Bernstein CN, Bitton A, Chan AK, Griffiths AM, Leontiadis G, Geerts W, Bressler B, Butzner JD, Carrier M, Chande N, Marshall JK, Williams C, Kearon C. Guidelines for the prevention and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology 2014;146:835-48.
  19. Thorlund K. Druyts E, Mills EJ, Fedorak RN, Marshall JK. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adults with no prior anti-TNF experience: an indirect comparison meta-analysis. J Crohn Colitis 2014;8:571-81.
  20. Narula N, Al-Dabbagh R, Dhillon A, Sands BE, Marshall JK. Anti-TNF-alpha therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2014;20:1862-9.
  21. Moayyedi P, Surette MG, Wolfe M, Kim PT, Taraschi R, Libertucci J, Armstrong D, Marshall JK, Kassam Z, Reinisch W, Lee C. A randomized placebo-controlled trial of fecal microbial therapy in ulcerative colitis: a mandate for further clinical trials. Gastroenterology 2015;149:102-9.
  22. Narula N, Fine M, Colombel JF, Marshall JK, Reinisch W. Systematic review: sequential rescue therapy in severe ulcerative colitis: do the benefits outweigh the risks? Inflamm Bowel Dis 2015;21:1683-94.
  23. Bressler B*, Marshall JK*, Bernstein CN, Bitton A, Jones J, Leontiadis GL, Panaccione R, Steinhart AH, Tse F, Feagan B, Toronto Ulcerative Colitis Consensus Group. Clinical practice guidelines for the medical management of ulcerative colitis: the Toronto Consensus. Gastroenterology 2015;148:1035-58 (*co-principal authors).
  24. Narula N, Marshall JK, Colombel JF, Leontiadis G, Williams JG, Muqtadir Z, Reinisch W. Systematic review and meta-analysis: infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids. Am J Gastroenterol 2016;111:477-91.
  25. Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J, Leontiadis GI, Tse F, Mahadevan U, Van der Woude J, IBD in Pregnancy Consensus Group. The Toronto consensus statements for management of IBD in pregnancy. Gastroenterology 2016;150:734-57.
  26. Fallone CA, Chiba N, Veldhuyzen van Zanten S, Fischer L, Gisbert J, Hunt R, Jones N, Render C, Leontiadis G, Moayyedi P, Marshall JK. Clinical practice guidelines for the treatment of Helicobacter pylori infection: the Toronto consensus. Gastroenterology 2016;151:51-69.
  27. Narula N, Cooray M, Anglin R, Narula A, Muqtadir Z, Marshall JK. Impact of high-dose vitamin D3 supplementation in treatment of Crohn’s disease in remission: a randomized double blind controlled study. Dig Dis Sci 2017;62:448-55.
  28. Ghosh S, Louis E, Beaugerie L, Bossuyt P, Bougen G, Bourreille A, Ferrante M, Franchimont D, Frost K, Hebuterne X, Marshall JK, O’Shea C, Rosenfeld G, Williams C, Peyrin-Biroulet L. Development of the IBD Disk: a visual self-administered tool for assessing disability in inflammatory bowel disease. Inflamm Bowel Dis 2017;23:333-40.
  29. Marshall JK, Bessette L, Thorne C, Shear NH, Lebovic G, Gerega SK, Millson B, Oraichi D, Gaetano T, Gazel S, Latour MG, Laliberte MC. Impact of the adalimumab patient support program’s care coach calls on persistence and adherence in Canada: an observational retrospective cohort study. Clin Ther 2018 [in press].